CN Mobile Logo


Colorectal Cancer

MBCC 2016 hero

Colorectal Cancer

A combination of four biomarkers may be able to help clinicians identify patients who have a high-risk type of colorectal cancer.

A short-course of preoperative radiation therapy plus consolidated chemotherapy was shown to be as effective as standard preoperative chemoradiation in the treatment of locally advanced rectal cancer.

There is clear proof of principle for adjuvant therapy in patients at high risk for tumor recurrence, such as those with resected metastatic colorectal cancer. For that reason, this strategy has been largely adopted, especially using 5-FU– and oxaliplatin-based regimens, thereby mirroring the approach in resected stage III colon cancer.

In all other settings, giving chemotherapy just to make us feel better emotionally in exchange for potential harm to the patient is not the right strategy. We need to find better treatments for this new clinical indication.

Here, we review the studies that have explored different treatment regimens, therapeutic sequencing, and biologic inclusions for the treatment of these patients, with neoadjuvant intent. We also describe how we have established our own treatment paradigm for the management of potentially curable metastatic colorectal cancer.

It remains difficult to decipher which patients are appropriate candidates for conversion therapy vs upfront surgery. Therefore, in predicting potential outcomes, several factors should be considered. Here, we will attempt to address such factors and provide insights.

The use of a reduced preparation CT colonography increased participation in colonography as a method of population screening for colorectal cancer, according to the results of a large Italian study.


Subscribe to Colorectal Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.